Showing results (301-310 of 391) with videos related to

Sort By:
Pageof 40
Clinical Pharmacology and Therapeutics|September 6, 2012
Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertensionK Eechoute, A A M van der Veldt, S Oosting, et al.
European Journal of Radiology|September 25, 2010
Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patientsIngrid M E Desar, Carla M L van Herpen, Jack J A van Asten, et al.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2017
Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trialPatrick Schöffski, Agnieszka Wozniak, Bernard Escudier, et al.
Cancers|July 24, 2021
Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen BlockadeGerben Lassche, Yuichiro Tada, Carla M L van Herpen, et al.
Cardiovascular and Interventional Radiology|December 7, 2019
Cost-Effectiveness of Drug-Eluting Stents for Infrapopliteal Lesions in Patients with Critical Limb Ischemia: The PADI TrialThijs Wakkie, Louise C D Konijn, Nils P C van Herpen, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|February 26, 2020
Impact of Time to Diagnosis and Treatment in Head and Neck Cancer: A Systematic ReviewHenrieke W Schutte, Floris Heutink, David J Wellenstein, et al.
International Journal of Cancer|November 21, 2019
Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patientsWim van Boxtel, Gerald W Verhaegh, Ilse A van Engen-van Grunsven, et al.
European Journal of Cancer (Oxford, England : 1990)|February 17, 2019
Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinomaW van Boxtel, L D Locati, A C H van Engen-van Grunsven, et al.
International Journal of Cancer|September 15, 2010
Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patientsIngrid M E Desar, J Hans F M Jacobs, Christina A Hulsbergen-vandeKaa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Molecular Tumor Boards: current practice and future needsD L van der Velden, C M L van Herpen, H W M van Laarhoven, et al.
Pageof 40